SAIF Advisors’s Sinovac Biotech SVA Stock Holding History
Bought
Maintained
Sold
Other funds holding SVA
NAH
SAIF Advisors's SVA Position: Q2 2021 in Review
SAIF Advisors held its Sinovac Biotech (SVA) position steady in Q2 2021 at 10,780,820 shares worth $405M. The position accounts for 92.64% of the portfolio, ranked #1.
SAIF Advisors first reported a position in SVA in Q4 2016 and has held it in 7 quarters since. 28 funds tracked by Wall St. Rank hold SVA as of Q2 2021.
- SAIF Advisors held 10,780,820 shares of Sinovac Biotech worth $405M as of Q2 2021.
- SAIF Advisors left its Sinovac Biotech share count unchanged in Q2 2021.
- Sinovac Biotech made up 92.64% of SAIF Advisors's portfolio in Q2 2021, its #1 holding.
- SAIF Advisors first reported a position in Sinovac Biotech in Q4 2016 and has held it in 7 quarters since.
- 28 funds tracked by Wall St. Rank held Sinovac Biotech as of Q2 2021.
Based on SAIF Advisors's 13F filing for Q2 2021, filed 11 Aug 2021.